An interventional study of Ropivacaine and Ultrasound-guided Nerve Block in Postoperative Pain After Cesarean Section, sponsored by Maternity Hospital - State Budgetary Institution of the Rostov Region, Taganrog. Recruiting at 1 site in Russia. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Maternity Hospital - State Budgetary Institution of the Rostov Region, Taganrog · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 184 studies testing ropivacaine in Pain, Postoperative — 20 open to participants now, 22 under way, 2 of them phase 3. Ropivacaine · Pain, Postoperative.
Among the 184 studies testing ropivacaine in Pain, Postoperative, this one is the 18th largest by planned enrollment, is one of 5 that started in 2026, is one of 61 with no phase, reaches primary completion later than 18 of the 21 other live ones, and was the 184th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →20 of the 184 studies testing ropivacaine in Pain, Postoperative are open now, in 10 countries. Recruiting first, the newest first:
Huazhong University of Science and Technology · Sites in China
Ages 18–80
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
Mount Sinai Hospital, Canada · Sites in Canada
Ages 18+ · Women only · Healthy volunteers
TLC Biopharmaceuticals, Inc. · Sites in United States
Ages 18–70
4th Military Clinical Hospital with Polyclinic, Poland · Sites in Poland
Ages 18–90
By country, each count listing its studies:
Ropivacaine: first FDA approval 1996 (NAROPIN). What it is approved for, and how studies give it, is on its page →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
184 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 24 · Phase 4 84
First in 2003; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 162 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 70 across the 184 interventional studies. Of the 125 that completed or were terminated, 32 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 184 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Maternity Hospital - State Budgetary Institution of the Rostov Region, Taganrog as lead sponsor.
Maternity Hospital - State Budgetary Institution of the Rostov Region, Taganrog has 1 study filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
6 of the studies testing ropivacaine in Pain, Postoperative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03230565Stanford UniversityContinuous Infusions vs Scheduled Bolus Infusions | 2026-12 |
| NCT06189781University of California, Los AngelesPain Injection Versus Epidural Anesthesia for Hip Surgery in Pediatric Patients With Cerebral Palsy | 2026-12-30 |
| NCT07099222University of ArizonaEfficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks | 2026-12-31 |
| NCT07704970Huazhong University of Science and TechnologyQLESP Block for Pain Control in Robotic Partial Nephrectomy | 2027-02-28 |
| NCT07853482Maternity Hospital - State Budgetary Institution of the Rostov Region, TaganrogTAP vs. ESP Blocks for Post-Cesarean Analgesia | 2027-05-10 |
Add all 6 to your calendar (.ics) → With an account.
Among the 184 studies testing ropivacaine in Pain, Postoperative, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study compares the effectiveness of two ultrasound-guided nerve blocks (TAP block and ESP block) versus standard pain management for relieving pain after a planned cesarean section.
Cesarean delivery often causes moderate to severe pain, which can be divided into somatic pain (from the abdominal incision) and visceral pain (from uterine contractions and internal tissues). While transversus abdominis plane (TAP) blocks are commonly used, erector spinae plane (ESP) blocks are a newer technique that may provide better relief for visceral pain.
In this randomized controlled trial, 162 women undergoing elective cesarean delivery under spinal anesthesia will be assigned to one of three groups:
The primary goal is to determine which method provides better control of visceral pain in the first 16 hours after surgery. Secondary goals include assessing somatic pain, time to first mobilization, time to first skin-to-skin contact with the baby, and the need for additional rescue pain medication. The study aims to support early recovery and improve mother-infant bonding by optimizing postoperative pain control.
Background:
Postoperative pain after cesarean delivery has a dual nature: a somatic component resulting from the abdominal wall incision and a visceral component arising from uterine contraction and tissue trauma (innervated by Th10-L1 segments). According to PROSPECT (2021) guidelines, multimodal analgesia is the standard of care. Interfascial plane blocks, such as the Transversus Abdominis Plane (TAP) block and the Erector Spinae Plane (ESP) block, have shown efficacy in controlling somatic pain. However, data comparing their differential efficacy on visceral versus somatic pain components are limited. The ESP block, performed at the L1 level, theoretically offers superior visceral analgesia due to the spread of local anesthetic to the dorsal rami of spinal nerves and potential craniocaudal spread into the paravertebral/epidural space.
Study Design:
This is a prospective, single-center, randomized, single-blind controlled trial conducted at the Maternity Hospital in Taganrog, Rostov Oblast, Russia. A total of 162 patients undergoing elective cesarean delivery under spinal anesthesia will be enrolled. Participants will be randomly assigned in a 1:1:1 ratio to one of three parallel groups:
All patients will undergo spinal anesthesia with hyperbaric bupivacaine 0.5% (2.2 mL) at the L2-L3 interspace. Preoperatively, pain threshold will be assessed using Nevidimova's method.
Outcome Measures:
The primary outcome is the intensity of visceral pain measured by the Numerical Rating Scale (NRS, 0-10) at 2, 4, 8, 12, and 16 hours postoperatively. Visceral pain is defined as dull, cramping lower abdominal pain.
Secondary outcomes include:
Statistical Analysis:
Based on a power analysis (80% power, α=0.05), a minimum of 54 patients per group (162 total) is required to detect a clinically significant difference of 1.5 points in visceral pain scores. Data will be analyzed using the Kruskal-Wallis test for between-group comparisons and the Friedman test for within-group dynamics. A p-value \< 0.05 will be considered statistically significant.
Ethical Considerations:
The study is conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. All participants will provide written informed consent. Personal data will be coded and stored securely. The study has been approved by the Local Ethics Committee of I.M. Sechenov First Moscow State Medical University.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive baseline multimodal analgesia (ketoprofen + paracetamol) PLUS bilateral ultrasound-guided ESP block at L1 level (20 mL of 0.375% ropivacaine per side). No trimeperidine is administered in this group.
Drug: Ropivacaine · Procedure: Ultrasound-guided Nerve Block · Drug: Ketoprofen and Paracetamol · Procedure: Ultrasound-guided ESP Block
Participants receive baseline multimodal analgesia (ketoprofen + paracetamol) PLUS bilateral ultrasound-guided TAP block (20 mL of 0.375% ropivacaine per side). No trimeperidine is administered in this group.
Drug: Ropivacaine · Procedure: Ultrasound-guided Nerve Block · Drug: Ketoprofen and Paracetamol · Procedure: Ultrasound-guided TAP Block
Participants receive baseline multimodal analgesia (ketoprofen + paracetamol) WITHOUT interfascial blocks. Rescue analgesia with trimeperidine 20 mg IM is available if NRS \> 4.
Drug: Ketoprofen and Paracetamol · Drug: Trimeperidine (Rescue)
0.375% solution for ultrasound-guided nerve blocks.
Bilateral TAP or ESP block performed in the post-anesthesia care unit.
Drug pages: KetoprofenStudies of KetoprofenKetoprofen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AcetaminophenStudies of AcetaminophenAcetaminophen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Baseline multimodal analgesia administered to ALL groups: Ketoprofen 100 mg IM at 4 hours postoperatively, followed by oral paracetamol + ketoprofen at 12 hours.
Rescue analgesia (Trimeperidine 20 mg IM) administered ONLY in the Control Group if NRS pain score \> 4.
Bilateral ESP block at L1 level with 20 mL of 0.375% ropivacaine per side.
Bilateral TAP block with 20 mL of 0.375% ropivacaine per side.
0.375% solution for nerve blocks.
Intensity of visceral pain at 16 hours postoperatively
Visceral pain intensity will be assessed using the Numerical Rating Scale (NRS, 0-10) at 2, 4, 8, 12, and 16 hours after surgery. The primary endpoint is the NRS score at 16 hours. Visceral pain is defined as dull, cramping lower abdominal pain.
Time frame: 2, 4, 8, 12, and 16 hours postoperatively
Intensity of somatic pain at 16 hours postoperatively
Somatic pain intensity (incisional pain) will be assessed using the Numerical Rating Scale (NRS, 0-10) at the same time points as visceral pain.
Time frame: 2, 4, 8, 12, and 16 hours postoperatively
Time to first independent mobilization
Time (in hours) from the end of surgery to the patient's first attempt to sit up or stand without assistance.
Time frame: Within 24 hours postoperatively
Time to first mother-infant skin-to-skin contact
Time (in hours) from the end of surgery to the first sustained skin-to-skin contact between the mother and the newborn.
Time frame: Within 24 hours postoperatively
Consumption of rescue analgesia
Number of patients requiring rescue analgesia (trimeperidine 20 mg IM) due to NRS pain score \> 4.
Time frame: Within 24 hours postoperatively
Incidence of adverse events
Frequency of hypotension, nausea, vomiting, pruritus, and signs of local anesthetic systemic toxicity (LAST).
Time frame: Within 24 hours postoperatively
Plan to share: No — Individual participant data will not be shared due to strict national regulations on the protection of personal health information in the Russian Federation and to ensure the complete confidentiality and privacy of study participants. Data will be available only to the principal investigator and the local ethics committee for verification purposes.
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for May 2027, 6 months after the start.
Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 6 months is below that.
Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ropivacaine